Clinical Trials Logo

Intracerebral Hemorrhage clinical trials

View clinical trials related to Intracerebral Hemorrhage.

Filter by:
  • Enrolling by invitation  
  • Page 1

NCT ID: NCT04733638 Enrolling by invitation - Clinical trials for Intracerebral Hemorrhage

ADVANCE- Automated Detection and Volumetric Assessment of ICH

Start date: January 26, 2021
Phase:
Study type: Observational

To evaluate the performance of the Viz ICH VOLUME algorithm.

NCT ID: NCT03865979 Enrolling by invitation - Clinical trials for Intracerebral Hemorrhage

AI ENRICH - AI Detection of ICH

Start date: January 23, 2020
Phase: N/A
Study type: Interventional

To evaluate the performance of the Viz RECRUIT software in subjects identified as symptomatic of a stroke event as determined by standard of care imaging assessments and interpretation.

NCT ID: NCT02920645 Enrolling by invitation - Clinical trials for Intracerebral Hemorrhage

Multicenter Validation of the AVICH Score

AVICH
Start date: September 2016
Phase: N/A
Study type: Observational

The primary objective of this multicenter study is to validate the AVICH score in terms of patient outcome prediction in AVM patients with associated ICH. Secondary objectives are the impact of pretreatment of the AVICH score. Patients outcome is measured using the modified Rankin Scale (mRS) and are grouped in favorable (mRS score, 0-2) and unfavourable (mRS score, 3-6) outcome at last follow-up (LFU). The following parameters, which are part of the AVICH score, will be compared between the 2 groups: ICH score including age, Glasgow Coma Scale (GCS) score, haemorrhage volume, presence of intraventricular hemorrhage (IVH), and localization of the ICH. Spetzler-Martin grade including AVM size, eloquent location, and venous drainage, as well as the Lawton-Young grade, including age, presence of ruptured AVM, and the nidus structure. In addition pre-/postruptured treatment modalities, including embolization, radiotherapy, surgery or no treatment will be analysed. Outcome (mRS) at 3 months, at 1 year, and at LFU will be compared. Multicentre validation study Key inclusion criteria: - All patients with ICH associated AVMs and a modified Rankin Scale <2 (so 0-1) before hemorrhage - Pretreatment (embolization, radiosurgery, surgery) before ICH is not an exclusion criteria. Key exclusion criteria: - incomplete data set - AVM Patients with only subarachnoid hemorrhage (SAH) or IVH and no ICH

NCT ID: NCT01918722 Enrolling by invitation - Clinical trials for Intracerebral Hemorrhage

Clinical Re-evaluation of Removing Blood Stasis Therapy in Treating Acute Cerebral Hemorrhage Safety and Efficacy

Start date: October 2013
Phase: Phase 4
Study type: Interventional

In order to investigate the time window of acute intracerebral hemorrhage(AICH) by "Blood Activating and Stasis Dispersing" therapy and to verify traditional methods if it would influence or enlarge the brain hematoma, test is made by random double-blind controlled. Patients are classified to (0-6h)and (6-72h) teams. Herbs is separated too. The period of the therapy lasts two weeks, and the follow up should last three months. The main indexes are mortality rate, disability rate and the brain hematoma situation. The review is made by the reference to (NIHSS),(GCS) and so on. So, the window time is determined through this test.